Regulatory and Biosafety Challenges for Vaccines

Authors

  • Fatemeh Nafian Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  • Simin Nafian Department of Stem Cell and Regenerative Medicine, Institute of Medical Biotechnology, National Institute Genetic Engineering & Biotechnology (NIGEB), Tehran, Iran
Abstract:

The global regulatory plan for vaccines provides a unique opportunity to develop safe and effective ones with assured quality. Methods used by regulators address challenges of new products and technologies and also increase understanding of benefits and risks of existing products. First, the laboratory-based regulatory sciences evolve correlates of immunity and safety; or improve the product characterization and potency assays. Second, these sciences design clinical trial tools to analyze novel benefit-risk methodologies for vaccines, and standardize regulatory processes. The aim of the Global regulatory agenda is to transform current national efforts into a coordinated execution plan to support worldwide immunization goals. In the current article, it has been defined the role of regulatory science to improved access to effective vaccines, and identified gaps that could be addressed through that. Also, the challenges of implementing a regulatory agenda have been investigated, and proposed strategies to resolve these gaps. In this way, an appropriate agenda will enable regulators, academics and other stakeholders to work in a coordinated way to innovate in the regulatory processes in support of global immunization goals.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Grand Challenges for Biosafety and Biosecurity

Success in the prevention and treatment of infectious diseases has saved more lives than any other achievement of medical science. The three greatest advances have been clean water, immunization, and the advent of antibiotics and, more recently, antivirals. Despite this record of success, we are far from conquering the grand challenge to human health posed by microbes. All that has been achieve...

full text

DNA vaccines: Mechanisms and aspects of relevance for biosafety

DNA vaccines represent a new approach to protect against infectious disease, and hence may improve human and animal welfare, reduce antibiotic usage and reduce the spread of pathogens. Edible and injectable DNA vaccines hold prospects for rapid immunization against a variety of diseases that are difficult to eradicate with traditional vaccines and antibiotics. Other potential uses of DNA vaccin...

full text

Challenges and opportunities in environmental biosafety research.

Since the first commercial release of genetically modified (GM, also referred to as genetically engineered, GE) crops in the middle of 1990s, the research and development of transgenic biotechnology has made dramatic progress. To date, global cultivation area of GM crops has exceeded 120 million hectares (James, 2009) with extensive cultivation of herbicide-tolerant soybean and canola, insect-r...

full text

Vaccines for neglected diseases: challenges and opportunities

Infectious diseases exert a major burden of disease in developing countries with 99% of the global burden of infectious diseases, as measured by DALYs, in low and middle income countries. While better use of existing vaccines would make an appreciable difference, the greatest burden is caused by diseases for which we currently have no vaccines. The picture, especially in children, is dominated ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 14  issue None

pages  17- 29

publication date 2020-03

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023